B cells in lupus erythematosus patients exhibit an autoreactive phenotype characterized by excessive activation and antibodies production. We reveal that ATR-mediated DNA damage response (DDR) drives the pathogenicity of B cell responses in SLE. Pharmacological targeting of ATR, attenuated B-cell immunogenic profile, proposing DDR as a novel therapeutic target.